| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.76 [0.65, 0.89] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.69 [0.57, 0.84] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.76 [0.66, 0.87] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | important | - |
| DCR | 1.15 [0.79, 1.68] | | > 1 | | 0% | 1 study (1/-) | 76.8 % | NA | not evaluable | | non important | - |
| DOR | 0.41 [0.20, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.17 [0.81, 1.69] | | > 1 | | 33% | 3 studies (3/-) | 80.0 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 4.25 [1.40, 12.93] | | < 1 | | 0% | 2 studies (2/-) | 0.5 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 3.17 [2.27, 4.43] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 1.37 [0.52, 3.62] | | < 1 | | 0% | 3 studies (3/-) | 26.5 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.36 [0.42, 4.40] | | < 1 | | 84% | 2 studies (2/-) | 30.5 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 1.24 [0.85, 1.81] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 2.37 [0.64, 8.73] | | < 1 | | 68% | 3 studies (3/-) | 9.8 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 3.81 [0.99, 14.59] | | < 1 | | 94% | 3 studies (3/-) | 2.6 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 2.02 [0.07, 61.28] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 2.67 [1.18, 6.03] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Arthralgia TRAE (grade 3-4) | 1.44 [0.48, 4.34] | | < 1 | | 0% | 1 study (1/-) | 26.0 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 2.47 [0.45, 13.60] | | < 1 | | 0% | 1 study (1/-) | 15.1 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Chorioretinopathy TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 10.35 [0.56, 190.49] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.30 [0.01, 6.77] | | < 1 | | 0% | 1 study (1/-) | 77.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 2.65 [0.07, 94.59] | | < 1 | | 82% | 2 studies (2/-) | 29.9 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Erythema TRAE (grade 3-4) | 7.41 [0.37, 148.78] | | < 1 | | 0% | 1 study (1/-) | 9.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 3.70 [0.38, 35.82] | | < 1 | | 0% | 1 study (1/-) | 13.1 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 8.25 [0.43, 156.83] | | < 1 | | 0% | 1 study (1/-) | 8.3 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 2.68 [0.24, 30.59] | | < 1 | | 0% | 2 studies (2/-) | 21.5 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 52.70 [7.19, 385.99] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 32.40 [7.79, 134.72] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.99 [0.64, 1.52] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.36 [0.78, 2.37] | | < 1 | | 0% | 1 study (1/-) | 14.1 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 2.46 [0.22, 27.26] | | < 1 | | 0% | 1 study (1/-) | 23.4 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.17 [0.02, 1.40] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 4.40 [0.69, 28.15] | | < 1 | | 0% | 2 studies (2/-) | 5.9 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.22 [0.24, 6.13] | | < 1 | | 0% | 1 study (1/-) | 40.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.33 [0.34, 5.18] | | < 1 | | 28% | 2 studies (2/-) | 33.9 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.48 [0.09, 2.52] | | < 1 | | 0% | 1 study (1/-) | 80.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.43 [0.11, 1.68] | | < 1 | | 0% | 1 study (1/-) | 88.8 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.17 [0.02, 1.39] | | < 1 | | 0% | 1 study (1/-) | 95.0 % | NA | not evaluable | | non important | - |
| Chills AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 2.04 [0.07, 60.99] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.76 [0.17, 3.43] | | < 1 | | 0% | 1 study (1/-) | 63.9 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 21.14 [1.23, 363.94] | | < 1 | | 0% | 1 study (1/-) | 1.9 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 16.77 [0.96, 293.61] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 2.44 [1.21, 4.94] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 4.12 [0.46, 37.08] | | < 1 | | 0% | 1 study (1/-) | 10.5 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 18.42 [5.64, 60.14] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 34.83 [8.39, 144.67] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 1.36 [0.30, 6.14] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 10.35 [0.56, 190.49] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 6.16 [0.31, 123.62] | | < 1 | | 0% | 1 study (1/-) | 12.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 2.07 [0.61, 6.95] | | < 1 | | 0% | 1 study (1/-) | 12.1 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 1.02 [0.06, 16.34] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
